For oral communications (including slides of lectures and posters), click here or scroll until after the publications.

See also my Google scholar

Selected publications


  • Artificial intelligence and mechanistic modeling for clinical decision making in oncology
    S. Benzekry
    Clinical Pharmacology and Therapeutics, 2020
  • Machine learning and mechanistic modeling for prediction of metastatic relapse in breast cancer
    C. Nicolo, C. Perier, M. Prague, G. MacGrogan, O. Saut, S. Benzekry
    JCO: Clinical Cancer Informatics, Volume 4, pp. 259-274, bioRxiv, 2020


    Contributions in Mathematical Oncology: When Theory Meets Reality
    HDR (Habilitation à diriger des recherches) thesis, defended November 13th, 2017


    Modeling spontaneous metastasis following surgery: an in vivo-in silico approach
    S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, J.M.L. Ebos
    Cancer Research, Volume 76, Issue 3, pp. 535-547, hal, 2016


    Mathematical modeling of tumor-tumor distant interactions supports a systemic anti-proliferative control of tumor growth
    S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, P. Hahnfeldt
    Cancer Research, Volume 77, Issue 18, pp.5183-5193, 2017


    Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
    M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy and S. Benzekry
    Scientific Reports, Volume 9, Issue 1, 13018, bioRxiv, hal, 2019


    Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth
    S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky, P. Hahnfeldt
    PLoS Computational Biology, Volume 10, Issue 8, e1003800, 2014


    Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
    D.C. Imbs*, R. El Cheikh*, A. Boyer, J. Ciccolini, C. Mascaux, B. Lacarelle, F. Barlesi, D. Barbolosi and S. Benzekry, * = equal contribution
    CPT Pharmacometrics Syst Pharmacol, Volume 7, Issue 1, pp. 42-50, hal, 2018


    Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
    C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, C. Poignard, J. ML Ebos, S. Benzekry
    PLoS Computational Biology, Volume 16, Issue 2, e1007178, bioRxiv, 2020


    Computational modelling of metastasis development in renal cell carcinoma
    E. Baratchart, S. Benzekry*, A. Bikfalvi*, T. Colin*, L.S. Cooley, R. Pineau, E. Ribot, O. Saut, W. Souleyreau, * = joint supervising authors
    PLoS Computational Biology, Volume 11, Issue 11, e1004626, hal, 2015


    Journal articles

      2020


    1. Artificial intelligence and mechanistic modeling for clinical decision making in oncology
      S. Benzekry
      Clinical Pharmacology and Therapeutics, 2020

    2. Machine learning and mechanistic modeling for prediction of metastatic relapse in breast cancer
      C. Nicolo, C. Perier, M. Prague, G. MacGrogan, O. Saut, S. Benzekry
      JCO: Clinical Cancer Informatics, Volume 4, pp. 259-274, bioRxiv, 2020

    3. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors
      C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, C. Poignard, J. ML Ebos, S. Benzekry
      PLoS Computational Biology, Volume 16, Issue 2, e1007178, bioRxiv, 2020

    4. Mechanistic learning for combinatorial strategies with immuno-oncology drugs: can model-informed designs help investigators?
      J. Ciccolini, D. Barbolosi, N. André, F. Barlesi, S. Benzekry
      JCO: Precision Oncology, , Volume 4, pp. 486-491, 2020

    5. Macro-scale models for fluid flow in tumour tissues: impact of microstructure properties
      C. Vaghi, R. Fanciullino, S. Benzekry, C. Poignard
      submitted, bioRxiv, 2020

    6. Descriptive and prognostic value of a computational model of metastasis in high-risk neuroblastoma
      S. Benzekry, C. Sentis, C. Coze, L. Tessonnier, N. André
      submitted, medRxiv, 2020

    7. A multi-layered systems approach for renal cell carcinoma
      L. Cooley, J. Rudewicz, W. Souleyreau, K. Clarke, F. Falciani, M. Dufies, S. Verbeke, A. Emanuelli, S. Benzekry, C. Taing, E. Ribot, S. Miraux, D. Lambrechts, E. Modave, R. Pineau, M-A Derieppe, D. Ambrosetti, J-C Bernhard, A. Ravaud, S. Negrier, J-M Ferrero, G. Pages, M. Nikolski, A. Bikfalvi submitted
      bioRxiv, doi:10.1101/670869, 2020


    8. 2019



    9. Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer
      M. Bilous, C. Serdjebi, A. Boyer, P. Tomasini, C. Pouypoudat, D. Barbolosi, F. Barlesi, F. Chomy and S. Benzekry
      Scientific Reports, Volume 9, Issue 1, 13018, bioRxiv, hal, 2019

    10. Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology
      A. Rodallec, R. Fanciullino, S. Benzekry, J. Ciccolini, EORTC PAMM group
      Anticancer Research, Volume 39, Issue 7, p. 3419-3422, hal, 2019

    11. Optimal Scheduling of Bevacizumab and Pemetrexed/cisplatin Dosing in Non-Small Cell Lung Cancer
      B. K Schneider, A. Boyer, J. Ciccolini, F. Barlesi, K. Wang, S. Benzekry* and J. P Mochel*, * = joint senior authors
      CPT Pharmacometrics Syst Pharmacol, Volume 25, hal, 2019

    12. CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies
      J. P Mochel, S. C Ekker, C. M Johannes, A. E Jergens, K. Allenspach, A. Bourgois-Mochel, M. Knouse, S. Benzekry, W. Wierson, A. K LeBlanc, S. S Kenderian
      AAPS J, Volume 21, Issue 3, p.50, hal, 2019


    13. 2018



    14. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
      A. Rodallec, G. Sicard, R. Fanciullino, S. Benzekry, B. Lacarelle, G. Milano, J. Ciccolini
      Expert Opin Drug Met, Volume 14, Issue 11, p. 1139-1147, 2018

    15. Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
      D.C. Imbs*, R. El Cheikh*, A. Boyer, J. Ciccolini, C. Mascaux, B. Lacarelle, F. Barlesi, D. Barbolosi and S. Benzekry, * = equal contribution
      CPT Pharmacometrics Syst Pharmacol, Volume 7, Issue 1, pp. 42-50, hal, 2018

    16. Dose- and time-dependence of the host-mediated response to paclitaxel therapy: a mathematical modeling approach
      M. Benguigui, D. Alishekevitz, M. Timaner, D. Shechter, Z. Raviv, S. Benzekry*, Y. Shaked*, * = joint senior authors
      Oncotarget, Volume 9, pp.2574-2590, 2018

    17. Pharmacokinetics of nanoparticles in oncology: clues for anticipating interpatient variability
      R. Fanciullino, S. Benzekry, B. Lacarelle, J. Ciccolini, A. Rodallec
      Critical Reviews in Oncology/Hematology, Volume 129, pp. 1-12, hal, 2018


    18. 2017



    19. Mathematical modeling of tumor-tumor distant interactions supports a systemic control of tumor growth
      S. Benzekry, C. Lamont, D. Barbolosi, L. Hlatky, P. Hahnfeldt
      Cancer Research, Volume 77, Issue 18, pp.5183-5193, 2017

    20. Non-Standard Radiotherapy Fractionations Delay the Time to Malignant Transformation of Low-Grade Gliomas
      A. Henares-Molina, S. Benzekry, P.C. Lara, M. Garcia-Rojo, V.M. Perez-Garcia and A. Martinez-Gonzalez
      PLoS One, Volume 12, Issue 6, e0178552, hal, 2017

    21. Model Driven Optimization of Antiangiogenics + Cytotoxics Combination: Application to Breast Cancer Mice Treated with Bevacizumab + Paclitaxel Doublet Leads to Reduced Tumor Growth and Fewer Metastasis
      S. Mollard, J. Ciccolini, D.C. Imbs, R. El Cheikh, D. Barbolosi, S. Benzekry
      Oncotarget, Volume 5, 10.18632/oncotarget.15484, 2017


    22. 2016



    23. In vivo bioluminescence tomography for monitoring breast tumor growth and metastatic spreading: comparative study and mathematical modeling
      S. Mollard, R. Fanciullino, S. Giacometti, C. Serdjebi, S. Benzekry, J. Ciccolini
      Scientific Reports, Volume 6, pp.36173, 2016

    24. Mathematical modeling of cancer immunotherapy and synergy with radiotherapy
      R. Serre, S. Benzekry, L. Padovani, C. Meille, N. André, J. Ciccolini, F. Barlési, X. Muracciole, and D. Barbolosi
      Cancer Research, Volume 76, Issue 17, pp. 4931–40, 10.1158/0008-5472.CAN-15-3567, 2016

    25. Modeling spontaneous metastasis following surgery: an in vivo-in silico approach
      S. Benzekry, A. Tracz, M. Mastri, R. Corbelli, D. Barbolosi, J.M.L. Ebos
      Cancer Research, Volume 76, Issue 3, pp. 535-547, 10.1158/0008-5472.CAN-15-1389, 2016


    26. 2015



    27. Computational modelling of metastasis development in renal cell carcinoma
      E. Baratchart, S. Benzekry*, A. Bikfalvi*, T. Colin*, L.S. Cooley, R. Pineau, E. Ribot, O. Saut, W. Souleyreau, * = joint supervising authors
      PLoS Computational Biology, Volume 11, Issue 11, e1004626, hal, 2015

    28. Metronomics reloaded: theoretical models bringing chemotherapy into the era of precision medicine
      S. Benzekry+, E. Pasquier+, D. Barbolosi, B. Lacarelle, F. Barlesi, N. Andre and J. Ciccolini
      Seminars in Cancer Biology, Volume 35, pp. 53-61, 10.1016/j.semcancer.2015.09.002, 2015

    29. Design Principles for Cancer Therapy guided by changes in complexity of Protein-Protein Interaction Networks
      S. Benzekry , J.A. Tuszynski, E.A. Rietman, G.L. Klement
      Biology Direct, Volume 10, Issue 32, 2015

    30. Host Age is a Systemic Regulator of Gene Expression Impacting Cancer Progression
      A. Beheshti, S. Benzekry, J.T. MacDonald, L. Ma, M. Peluso, P. Hahnfeldt, L. Hlatky
      Cancer Research, Volume 75, Issue 6, pp. 1134-43, 2015


    31. 2014



    32. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth
      S. Benzekry, C. Lamont, A. Beheshti, A. Tracz, J.M.L. Ebos, L. Hlatky, P. Hahnfeldt
      PLoS Computational Biology, Volume 10, Issue 8, e1003800, 2014

    33. Global Dormancy of Metastases due to Systemic Inhibition of Angiogenesis
      S. Benzekry, A. Gandolfi, P. Hahnfeldt
      PLoS One, Volume 9, Issue 1, e84249, 2014



    34. 2013



    35. Maximum Tolerated Dose Versus Metronomic Scheduling in the Treatment of Metastatic Cancers
      S. Benzekry, P. Hahnfeldt
      Journal of Theoretical Biology, Volume 335, pp. 235-244, 2013


    36. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice
      F. Lignet, S. Benzekry, S. Wilson, F. Billy, O. Saut, M. Tod, B. You, A. Adda Berkane, S. Kassour, M.X. Wei, E. Grenier, B. Ribba
      Journal of Theoretical Biology, Volume 320, pp. 86-99, 2013


    37. 2012



    38. Modelling the impact of anticancer agents on metastatic spreading
      S. Benzekry, N. André, A. Benabdallah, J. Ciccolini, C. Faivre, F. Hubert and D. Barbolosi
      Mathematical Modeling of Natural Phenomena , Volume 7, Issue 1, pp. 306 - 336, 2012

    39. A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
      S. Benzekry, G. Chapuisat, J. Ciccolini, A. Erlinger and F. Hubert
      Comptes Rendus de l'Académie des Sciences - Mathématiques, Volume 350, Issue 1-2, pp. 23-28, 2012

    40. Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers
      S. Benzekry
      ESAIM: Mathematical Modelling and Numerical Analysis, Volume 46, Issue 2, pp. 207-237, hal, 2012.


    41. 2011



    42. Passing to the limit 2D-1D in a model for metastatic growth
      S. Benzekry
      Journal of Biological Dynamics, Volume 6, Suppl. Issue 1, pp. 19-30, hal, 2011

    43. Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis,
      S. Benzekry
      Journal of Evolution Equations Volume 11, Issue 1, pp. 187-213, hal, 2011

    Book chapters, editorials, proceedings and protocols


    1. Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: the PIONeeR and QUANTIC joint-projects
      J. Ciccolini, S, Benzekry, F. Barlesi
      British Journal of Cancer, 2020

    2. Prédiction de l’efficacité de l’immunothérapie dans le cancer bronchique à partir de données cliniques et biologiques simples : apport de l’intelligence artificielle
      M. Grangeon, S. Benzekry, S. Chaleat, P. Tomasini, D. Barbolosi, F. Barlesi, L. Greillier
      Revue des Maladies Respiratoires, Volume 12, Issue 1, pp. 217, hal, 2020

    3. Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess
      J. Ciccolini, N. Andre, D. Barbolosi, S. Benzekry, F. Barlesi
      Annals of Oncology, Volume 62, Issue 2, hal, 2019

    4. Population Modeling of Tumor Growth Curves, the Reduced Gompertz Model and Prediction of the Age of a Tumor.
      C. Vaghi, A. Rodallec, R. Fanciullino, J. Ciccolini, J. Mochel, M. Mastri, J. ML Ebos, C. Poignard and S. Benzekry
      In G. Bebis, T. Benos, K. Chen, K. Jahn, & E. Lima (Eds.), (pp. 87–97). Presented at the Mathematical and Computational Oncology, Cham: Springer International Publishing, 2019

    5. Abstract 4264: Mathematical modeling of differential effects of Sunitinib on primary tumor and metastatic growth.
      C. Nicolo, M. Mastri, J. ML Ebos, S. Benzekry
      Cancer Research, Volume 78, Issue 13 (Supplement), 4264, 2018

    6. Etude de l’effet séquence bevacizumab/pemetrexed/cisplatine chez la souris porteuse de cancer du poumon non à petites cellules.
      A. Boyer, J. Ciccolini, C. Mascaux, D.C. Imbs, R. El Cheikh, F. Barlesi, and S. Benzekry
      Revue des Maladies Respiratoires, 34:A52, 2017

    7. Abstract 4529: Optimization of the sequence for the administration of bevacizumab in combination with pemetrexed and cisplatin in NSCLC : a pharmacology based in vivo study A., Boyer, D.C. Imbs, R.E. Cheikh, C. Mascaux, F. Barlesi, D. Barbolosi, S. Benzekry, and J. Ciccolini.
      Cancer Research, Volume 77, Issue 13 (Supplement), 4529, 2017

    8. Optimized radiotherapy protocols delay the malignant transformation of low-grade gliomas in-silico
      A. Henares-Molina, S. Benzekry, P. Lara, M. García-Rojo, V. Pérez-García, and A. Martínez-González
      Neuro-Oncology, 19 (suppl 3):iii12–iii12, 2017

    9. Les lois de la croissance tumorale
      S. Benzekry
      Bibliothèque Tangente, Hors-série Maths et Médecine, 2016

    10. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai.
      Pantziarka, P., Hutchinson, L., André, N., Benzekry, S., Bertolini, F., Bhattacharjee, A., et al.
      ecancermedicalscience, 10, 2016

    11. On the growth and dissemination laws in a mathematical model of metastatic growth
      S. Benzekry, J. ML Ebos
      ITM Web of Conferences, Volume 5, 10.1051/itmconf/20150500007, 2015

    12. Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support
      J. Ciccolini, S. Benzekry, B. Lacarelle, D. Barbolosi and F. Barlési
      Proc Natl Acad Sci USA, Volume 112, Issue 27, 10.1073/pnas.1506689112, 2015

    13. Capturing the Driving Role of Tumor-Host Crosstalk in a Dynamical Model of Tumor Growth
      S. Benzekry, A. Beheshti, P. Hahnfeldt, L. Hlatky
      bio-protocol, Volume 5, Issue 21, e1644, hal, 2015

    14. Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxic modalities: application to the bevacizumab-paclitaxel association in breast cancer models S. Mollard, S. Benzekry, S. Giacometti, C. Faivre, F. Hubert, J. Ciccolini and D. Barbolosi.
      Cancer Research, Volume 74, Issue 19 (Supplement), 3677, 2014

    15. A Mathematical Model for Growing Metastases on Oncologists’s Service
      D. Barbolosi, A. Benabdallah, S. Benzekry, J. Ciccolini, C. Faivre, F. Hubert, F. Verga, B. You
      In Computational Surgery and Dual Training, Springer New York, pp. 331-338, 2014

    16. A mathematical model of systemic inhibition of angiogenesis in metastatic development
      S. Benzekry, A. Gandolfi, P. Hahnfeldt
      ESAIM: Proceedings, Volume 45, pp. 75-87, 2014

    Foreign research visits

    Fall 2016. Short sabbatical at the Roswell Park Cancer Institute to work with John ML Ebos, Buffalo, NY, USA.

    September 2015. Invited researcher in the Môlab to work with Alicia Martinez-Gonzalez and Victor Pérez-Garcia, Ciudad Real, Spain.

    January 2012 - November 2012. Postdoc at the Center of Cancer and Systems Biology, Boston, USA.

    May 2011. Instituto di Analisi dei Sistemi ed Informatica ''Antonio Ruberti'', Consiglio Nazionale delle Ricerche. Research visit with Alberto Gandolfi and collaboration with Alberto d'Onofrio, from the European Institute of Oncology from Milan. Rome, Italy.

    March - June 2007. Master 2’s intership in the mathematical department of the Polytechnical University of Catalonia : Exploration of deterministics and stochastics neuronal reds. Barcelona, Spain.


    Invited talks


    1. May, 2020, CIMPA Research Summer School on Mathematical models applied to molecular dynamics and oncology. Santiago de Cuba, Cuba.

    2. April 2020, 10th European Lung Cancer Congress (ELCC). Geneva, Switzerland.

    3. January, 2020, Second philosophy of cancer workshop. Quantitative modeling of metastasis: cancer at the organism scale. Bordeaux, France. (Slides)

    4. July 2019, International Society of Pharmacometrics (ISoP) workshop. Paris, France. (Slides)

    5. May 2019, Masterclass Mathematiques appliquees CEPS Mathematiques Des Sciences du Vivant, CIRM, Marseille, France. Data-driven mechanistic modeling of metastasis: cancer at the organism scale.

    6. May 2019, NCI Mathematical Oncology Meeting, Portland, USA. Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer.(Slides)

    7. May 2019, RITS conference (Recherche en Imagerie et Technologies pour la Sante) of the French Society of Biomedical Engineering (SFGBM), Tours, France. Data-driven mechanistic modeling of metastasis: cancer at the organism scale. (Slides)

    8. November 2018, Mathematical Challenges in the Analysis of Continuum Models for Cancer Growth, Evolution and Therapy, Oaxaca, Mexico. (Slides)

    9. July 2018, Mathematical perspectives in the biology and therapeutics of cancer, Marseille, France. (Slides)

    10. July 2018, Annual Workshop on Mathematics in Medicine, Wolfgang Pauli Institute, Vienna, Austria. (Slides)

    11. June 2018, 3rd Mathematical Biology Modelling Days, Besançon, France. (Slides)

    12. February 2018, CMM-Fields-Inria Workshop on Mathematics for Medicine, Toronto, Canada.

    13. January 2018, Conference on Statistics and Health, Toulouse, France.

    14. December 2017, Mathematical methods and modeling of biophysical phenomena. Mathematical modeling and prediction of metastasis. Rio de Janeiro, Brazil.

    15. September 2017, Première session du GDR MAMOVI. Mathematical Modeling and Prediction of Clinical Brain Metastases in Non-Small Cell Lung Cancer. Lyon, France

    16. June 2017, XXV Congreso de ecuaciones diferenciales y aplicaciones / XV congreso de matematica aplicada, Optimization of the timing of sequential administration of bevacizumab plus cytotoxics in non-small cell lung cancer by a mathematical model. Cartagena, Spain.

    17. May 2016, Metronomics @ Mumbai. Mathematical modeling of chemotherapy scheduling. Mumbai, India.

    18. December 2015, Present challenges of mathematics in oncology and biology of cancer. Marseille, France.

    19. November 2015, Dynamique et contrôle des croissances tumorales, Rouen, France.

    20. November 2015, Contrôle des EDP et applications , Marseille, France.

    21. October 2015, Journées du Groupe de Métabolisme et Pharmacocinétique , Paris, France.

    22. June 2015, Micro and Macro Systems in Life Sciences (MMSLS 2015), Bedlewo, Poland.

    23. March 2015, Workshop on hybrid and multiscale modelling in cell and cell population biology , Laboratoire Jacques-Louis Lions. Combined in vivo and in silico quantitative modeling of post-surgery metastatic development. Paris, France.

    24. March 2015, Mathematical Methods and Modeling of Biophysical Phenomena, Cabo Frio, Rio de Janeiro, Brazil.

    25. January 2015, 36th EORTC PAMM Winter meeting , Marseille, France.

    26. October 2014, Autumn School by Japanese and French Mathmaticians . Mathematical modeling of tumor growth and metastatic spread. Data, theories and predictions. Osaka, Japan.

    27. July 2014, 10th AIMS Conference on Dynamical Systems, Differential Equations and Applications . A mathematical model of systemic inhibition of angiogenesis in metastatic development. Madrid, Spain.

    28. November 2013, French-Mexican Meeting on Industrial and Applied Mathematics, Villahermosa, México. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth

    29. May 2013, Bi-annual congress of the SMAI. Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics. Seignosse, France.

    30. March 2013, Workshop on Mathematical Methods and Modeling of Biophysical Phenomena, Cabo Frio, Brazil. Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics

    31. July 2012, 2nd Annual Workshop on Cancer Systems Biology — Tumor Metronomics: Timing and Dose Level Dynamics, Center for Cancer and Systems Biology, Boston. Mathematical modeling of metastatic development and scheduling optimization of anti-cancerous therapies

    32. March 2012, Thematic school : "Present challenges of mathematics in oncology and biology of cancer", CIRM, Marseille. A modeling approach for therapies in metastatic cancers

    33. October 2011, Journées du Groupe de Métabolisme et Pharmacocinétique. Paris. Poster and Oral communication, Biomathematical modeling for description of metastatic processes and optimization of combined anti-angiogenic + cytotoxic therapies.

    34. July 2011, Workshop on Systems Biology of Tumor Dormancy. St. Elizabeth's Medical Center, Boston USA. A modelling approach for therapies in metastatic cancers.

    35. July 2011, 7th Congrès International Congress on Industrial and Applied Mathematics - ICIAM 2011, Vancouver. Mathematical modeling of the metastatic process and optimization of anti-cancerous therapies.

    36. May 2011, ``Emergence'' day of the Institut Gustave Roussy (IGR).Un exemple de modélisation du processus métastatique. Paris, France.

    37. June 2010, CANUM 2010, A model of metastatic growth under angiogenic control. Gironde, France.

    38. May 2010, AIMS Dresde. Modeling and mathematical analysis of metastatic growth under angiogenic control. Dresden, Germany

    39. March 2010, 2nd Workshop on Metronomic Anti-Angiogenic Chemotherapy in Paediatric Oncology. Mathematical modeling of MTD and metronomic temozolomide. Marseille, France.

    Seminars (invited)


    1. June 2019, Seminar in the Novartis pharmacometrics department. Basel, Switwerland. Artificial intelligence and machine learning in oncology: myths and reality.

    2. May 2019, Biomedicum Helsinki Seminar (Invitation by Sampsa Hautaniemi), Faculty of Medicine, Helsinki, Finland.

    3. May 2019, Seminaire phases I en oncologie, Marseille, France. Old concept, new name? l’intelligence artificielle en oncologie.

    4. November 2018, Probability and Statistics seminar, Institut Elie Cartan de Lorraine, Nancy, France.

    5. February 2018, Seminar at the Roswell Park Cancer Institute (Invitation by Dr. J. Ebos), Buffalo, USA.

    6. December 2017, Seminar at the Rappaport Faculty of Medicine of the Technion Israel Institute of Technology (invitation by Yuval Shaked). Contributions in Mathematical Oncology: When Theory Meets Reality. Haifa, Israel.

    7. May 2017, Laboratoire d'Analyse Topologie et Probabilites, Institut de Mathematiques de Marseille. Mathematical Oncology: Theory Meets Reality. Marseille, France.

    8. November 2016, Integrated Mathematical Oncology Department, Moffitt Cancer Center.Mathematical Modeling of Metastasis: Theory Meets Reality. Tampa, Florida, USA.

    9. October 2016, Department of Genetics, Roswell Park Cancer Institute (invitation by John ML Ebos). Mathematical Modeling of Metastasis: Theory Meets Reality. Buffalo, NY, USA.

    10. October 2016, Robert Kerbel's laboratory at Sunnybrook Research Institute. Mathematical Modeling of Metastasis: Theory Meets Reality. Toronto, Canada.

    11. October 2016, Mathematics Department Colloquium, Ryerson University. Mathematical Modeling of Metastasis: Predicting the invisible. Toronto, Canada.

    12. May 2016, Seminar at the laboratory of Génétique, Immunothérapie, Chimie et Cancer of the University of Tours. Data-based mathematical modeling analysis of preclinical studies in oncology. Tours, France.

    13. January 2016, Seminar at the laboratoire d'imagerie biomédicale. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Paris, France.

    14. March 2014, Seminar at the Inria team Dracula. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. Lyon, France.

    15. April 2013, Seminar of the ANEDP team . Mathematical modeling of systemic inhibition of angiogenesis and metastatic dynamics. Orsay, France.

    16. February 2013, Seminar of the LATP, Marseille, France. A math walk in a biology lab

    17. November 2011, EDP seminar of the mathematics lab in Besançon. Modélisation et analyse mathématique de thérapies anti-cancéreuses pour les cancers métastatiques

    18. May 2011, Seminar at the Instituto di Analisi dei Sistemi ed Informatica ``Antonio Ruberti'', Rome. A modelling approach for the metastatic process.

    19. May 2010, Seminar Maths-Bio of the university Lyon 1. Modeling and mathematical analysis of metastatic growth under angiogenic control. Lyon, France

    Accepted oral communications


    1. August 2020, Virtual Physiological Human 2020 (VPH2020), Paris, France. Descriptive and prognostic value of a computational model of metastasis in high-risk neuroblastoma. Oral

    2. June 2019, Population Approach Group meeting in Europe (PAGE), Stockholm, Sweden. Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer. Oral

    3. June 2019, Population Approach Group meeting in Europe (PAGE), Stockholm, Sweden. Machine learning combined to mechanistic modeling of differential effects of neo-adjuvant Sunitinib on primary tumor and metastatic growth. Oral (senior author, first author and speaker C. Nicolo)

    4. August 2018, 17th Biennial Congress of the Metastasis Research Society, Princeton, NJ, USA. A biologically-based mathematical model for prediction of metastatic relapse. Poster.

    5. July 2018, Mathematical perspectives in the biology and therapeutics of cancer, Marseille, France. Improving intra-tumor drug distribution of anti-cancer nanoparticles by data-informed mathematical modeling. Oral (senior author, first author C. Vaghi).

    6. June 2018, Data science summer school, Polytechnique, Palaiseau, France. Improving intra-tumor drug distribution of anti-cancer nanoparticles by data-informed mathematical modeling. Poster (senior author, first author C. Vaghi. Won the best poster award)

    7. June 2018, Data science summer school, Polytechnique, Palaiseau, France. Poster

    8. May 2018, Population Approach Group in Europe (PAGE) meeting, Montreux, Switzerland. Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin. Poster (co-senior author with J. Mochel, first author B. Schneider).

    9. April 2018, Annual meeting of the AACR, Chicago, USA. Mathematical modeling of differential effects of Sunitinib on primary tumor and metastatic growth. Poster (senior author, first author C. Nicolo).

    10. March 2017, 38th EORTC-PAMM Winter meeting, Split, Croatia. Optimization of the timing of sequential administration of bevacizumab plus cytotoxics in NSCLC by a mathematical model.

    11. October 2015, Journées du cancéropôle Grand Sud-Ouest , Bordeaux, France. Poster. Modeling spontaneous metastasis following surgery: an in vivo-in silico approach

    12. June 2015, Mathematical Methods in Systems Biology, Dublin, Ireland.

    13. June 2014, European Conference on Mathematical and Theoretical Biology , Göteborg, Sweden. Metastatic dynamics, systemic inhibition of angiogenesis and implications for surgery

    14. June 2014, International Tumor Dormancy Symposium , Lille, France. Metastatic dynamics and systemic inhibition of angiogenesis. Implications for dormancy and surgery (Poster)

    15. February 2014, Demonstration during the inria-industry meeting, Lyon, France. Mathematical Models in Preclinical Cancer Research

    16. January 2014, Seminar at the ISPED. Classical Mathematical Models for Description and Forecast of Preclinical Tumor Growth. Bordeaux, France.

    17. June 2011, 8th European Conference on Mathematical and Theoretical Biology - ECMTB 2011 and Annual Meeting of The Society for Mathematical Biology, Kraków. Optimal schedules for therapies in metastatic cancers .

    18. May 2010, CMPD 3, Bordeaux. Modeling and mathematical analysis of metastatic growth under angiogenic control.

    19. November 2009, Conference of biomathematics et biomechanics, Tozeur, Tunisie. Presentation of a poster.

    20. August 2009, CEMRACS. Asymptotic behavior of the solutions of the renewal equation and Angiogenesis modeling.

    21. June 2009, Bucolic days of the student's seminar of the LATP.

    22. November 2008, Workgroup Maths-Cancer of Marseille. About the article "A theoretical study of the response of vascular tumours to different types of chemotherapy" de J. Panovska, H. M. Byrne et P. K. Maini.

    Participation to conferences and summer schools

    6-8 June 2011, Biomat 2011, Perspectives in Mathematics and Life Sciences.

    3-4 Février 2011, Journées Louis Antoine "Nonlocal equations and population adaptive dynamics".

    2 December 2010. Thematic day "Models and imaging in oncology", Paris, France.

    30 November - 1er December 2009. Symposium "Health and complex systems" of the Entretiens Jacques Cartier, Lyon, France.

    20-23 November 2009. Conference of biomathématics et biomechanics, Tozeur, Tunisie.

    20 July - 28 August 2009. CEMRACS'09 Mathematical modeling in Medicine. Project Angio. CIRM, Marseille, France.

    2 - 13 February 2009. Advanced courses and conferences in mathematical biology : modeling and differential equations. CRM, Barcelone, Espagne.

    18 - 19 December 2008. Pharmacokinetics and pharmacodynamics of anticancerous drugs : resistances and synergies. Centre de recherche des cordeliers, Paris.